Lab
Religen
Religen was paid $1.67M by Medicaid between Dec 2019 and Dec 2023, across 7 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 66% of everything it billed.
33Billing provider infoRELIGEN
PLYMOUTH MEETING, PA 19462
PLYMOUTH MEETING, PA 19462
33aNPI1629579826assigned 02/22/2018
33bProvider typeClinical Medical Laboratory
28Total paid$1.67M
24GClaims136,294
24DCodes billed7
24AFirst – last monthDec 2019 – Dec 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Pennsylvania
Rank by total paid#19 of 95
Median peer was paid$153K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 25 | $22K | |
| 2020 | 182 | $10K | |
| 2021 | 54,354 | $858K | |
| 2022 | 68,188 | $698K | |
| 2023 | 13,545 | $78K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 66% | 45,094 | 21,844 | $1.11M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 22% | 44,807 | 21,616 | $373K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9.5% | 44,639 | 21,545 | $159K |
| 81412 | 1.3% | 25 | 12 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 119 | 113 | $5K |
| 99001 | <1% | 121 | 113 | $17.04 | |
| 87631 | 0% | 1,489 | 199 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAWANT, BHOOSHAN (OWNER)